Exchange Traded Concepts LLC Reduces Position in Omnicell, Inc. $OMCL

Exchange Traded Concepts LLC trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 54.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 17,308 shares of the company’s stock after selling 20,520 shares during the period. Exchange Traded Concepts LLC’s holdings in Omnicell were worth $527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Qube Research & Technologies Ltd grew its stake in Omnicell by 38.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock valued at $19,227,000 after purchasing an additional 181,394 shares during the last quarter. Strs Ohio purchased a new position in shares of Omnicell in the first quarter worth about $5,635,000. Liontrust Investment Partners LLP lifted its holdings in shares of Omnicell by 81.2% during the second quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company’s stock worth $9,358,000 after purchasing an additional 142,629 shares during the period. Assenagon Asset Management S.A. boosted its position in Omnicell by 1,316.2% in the third quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock valued at $4,284,000 after buying an additional 130,742 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Omnicell in the first quarter valued at approximately $4,394,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on OMCL shares. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Benchmark boosted their target price on shares of Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $43.00.

Omnicell Trading Down 0.5%

OMCL stock opened at $45.92 on Wednesday. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $47.69. The company has a quick ratio of 1.21, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. The firm has a market cap of $2.06 billion, a P/E ratio of 106.79, a PEG ratio of 5.05 and a beta of 0.83. The company’s 50-day simple moving average is $38.48 and its 200-day simple moving average is $33.26.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.